How Does Flow Rate Affect the Binding Capacity of Purexa™ Membranes?
The Role of Flow Rate and Binding Capacity in Chromatography
At Purilogics, we take pride in designing and developing membrane chromatography technologies for biologics purification. Our mission is to provide rapid and effective purification solutions to help the biopharmaceutical industry simplify biologics purification. With the use of our products, purification can be completed in a matter of minutes, rather than hours. This can be attributed to the ability of our membranes to maintain a high dynamic binding capacity (DBC) at rapid flow rates. DBC indicates how much target biologic (e.g. antibody, recombinant protein, mRNA, plasmid DNA, etc.) can bind to the membrane before reaching a point of significant loss. Thus, DBC is an important value to consider when evaluating productivity of chromatography products. Leading resin chromatography products must sustain a long residence time to achieve a high DBC, significantly hindering productivity and contributing to the downstream processing bottlenecks.
Considering this reality, one may ask, “how does the flow rate impact the binding capacity of Purexa™ membranes?”. According to the internal research and external validation, we have confirmed that the DBC of the membrane is not significantly impacted by the flow rate.
Figure 1: Purexa™ MQ DBC vs. Flow Rate
Purexa™ MQ
Purexa™ MQ is a multimodal anion-exchange membrane. To determine the impact of flow rate on the binding capacity of Purexa™ MQ, we tested the DBC of the membrane using salmon sperm DNA (120,000 – 300,000 Dalton) and Bovine Serum Albumin (BSA; 60,000 Dalton) at 10 Membrane Volumes per minute (MV/min) and 50 MV/min. Results of this experiment can be noted in Figure 1: Purexa™ MQ DBC vs Flow Rate.
Purexa™ MQ can be applied for various purifications, including:
Monoclonal Antibody
Recombinant Antibody
RNA; mRNA
Nucleotide/Nucleoside
DNA; Plasmid DNA
Viruses; Virus-Like Particles (VLP)
Viral Vectors — AAV, Lentiviral Vectors (LV)
Antibody Drug Conjugates
Figure 2: Purexa™ PrA DBC vs. Flow Rate
Purexa™ PrA
Purexa™ PrA is Purilogics’ innovative Protein A based affinity membrane chromatography product. We evaluated the DBC of the membrane at five flow rates (6.25 MV/min, 12.5 MV/min, 25 MV/min, 50 MV/min, 104 MV/min) using 2 mg/mL polyclonal human antibody as the target molecule. Results of this experiment can be observed in Figure 2: Purexa™PrA DBC vs Flow Rate.
Applications of Purexa™ PrA include:
Antibdody capture-step purification
Cell line development
High-throughput antibody purification
Rapid mAb purification
Purexa™ OdT
Figure 3: Purexa™ OdT DBC vs. Flow Rate
Currently, Purilogics is developing an oligo deoxythymidine (OdT) based affinity membrane for the enhanced purification of mRNA. In order to analyze the productivity of this particular membrane, we tested the DBC using 800 base mRNA at four flow rates (5 MV/min, 10 MV/min, 20 MV/min, and 40 MV/min). Results of this experiment are displayed in Figure 3: Purexa™ OdT DBC vs Flow Rate. Please reach out to our team to initiate collaboration with Purilogics regarding Purexa™ OdT membrane.
As shown by the figures above, our membranes maintain a very high binding capacity under elevated flow rates. If you are interested in our membrane chromatography products, please feel free to contact us!
Check out our full product lineup here